Faculty profile

Dalia Barsyte-Lovejoy

ResearcherPharmacology and ToxicologyUniversity of Toronto

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses may be missing. Find their university profile.

Dalia Barsyte-Lovejoy

Researcher

Pharmacology and Toxicology

Health Sciences

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
38 publications in the last five years, latest in 2026.
Senior (last) author on 6 recent papers, a sign of leading a research group.
Principal investigator on 5 research grants (3 CIHR, 2 NSERC), most recently in 2023.
Supervised 2 trainees who won CIHR awards, most recently in 2023.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

347

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Posttranslational Modifications Tumor Immunity Pancreatic Cancer Splicing

Latest papers

Identification of E3 ligase substrates and PROTAC-induced ubiquitylation sites using proximity-based identification of ubiquitin sites (PrIUS).
Communications biology · 2026
ABHD2 activity is not required for the non-genomic action of progesterone on human sperm.
Human reproduction (Oxford, England) · 2026
Development of a Dual Chemical Probe for the USP16 and HDAC6 Zinc-Finger Ubiquitin-Binding Domain.
Journal of medicinal chemistry · 2026

All 96 publications

Latest funding

Chemical technologies for controlling T cell glycosylation in health and disease
CIHR · 2024 · Co-investigator
$956,250
Mapping pathogenic chromatin complexes in advanced prostate cancer with ChemBioID
CIHR · 2023 · Supervisor
$135,000
Targeting protein arginine methylation in the 9p21.3 loss tumor microenvironment
CIHR · 2023 · Nominated PI
$902,700

All 8 grants and awards

96 publications.

Identification of E3 ligase substrates and PROTAC-induced ubiquitylation sites using proximity-based identification of ubiquitin sites (PrIUS).

Tessier TM, Maitland MER, Kutera M, Dybas JM, St-Germain J, Arrowsmith CH, Barsyte-Lovejoy D, Zhang W, Raught B, Weitzman MD

Communications biology2026

DOI: 10.1038/s42003-026-09964-6 PMID: 41957433

ABHD2 activity is not required for the non-genomic action of progesterone on human sperm.

Edwards M, Amaral A, Carter EM, Arnolds O, Vester K, Thrun A, Wigren E, Homan E, Ribera P, Bentley K, Haraldsson M, Theo-Emegano N, Loppnau P, Szewczyk MM, Cao MA, Barsyte-Lovejoy D, Dittmar N, Hans A, Weber M, Münchow J, Zhu WF, Temme L, Brenker C, Strünker T, Sundström M, Todd MH, Edwards AM, Lesche R, Gileadi O, Tredup C

Human reproduction (Oxford, England)2026

DOI: 10.1093/humrep/deag085 PMID: 42212558

Development of a Dual Chemical Probe for the USP16 and HDAC6 Zinc-Finger Ubiquitin-Binding Domain.

Silva M, Mann M, Mirabi B, Szewczyk MM, Loup J, Dupeux A, Chandrasekaran R, Bajohr J, Arrowsmith C, Schapira M, Lautens M, Barsyte-Lovejoy D, Harding RJ, Santhakumar V

Journal of medicinal chemistry2026

DOI: 10.1021/acs.jmedchem.5c02976 PMID: 41718545

Meeting report on FASEB protein arginine methylation: mechanism to therapeutics.

Shechter D, Huang R, Shah P, Dubois T, Li XM, Parhitko A, Bedford MT, Kuang S, Chen T, Yang Y, Rajyaguru P, Barsyte-Lovejoy D, Zhao X, Xu W, Davies CC, Tikhanovich I, Tran NT, Kako K, Hashimoto M, Luo M, Hevel JM, Fukamizu A, Yu MC

The Journal of biological chemistry2026

DOI: 10.1016/j.jbc.2026.111448 PMID: 41967639

PRMT1 inhibitor MS023 suppresses RNA splicing to sensitize small cell lung cancer to DNA damaging agents.

Aparnathi MK, Ul Haq S, St-Germain J, Nixon KCJ, Walton J, Song L, Majeed S, Patel PS, Subramaniam R, Philip V, Marcellus R, Barsyte-Lovejoy D, Al-Awar R, Hakem R, Arrowsmith CH, Ailles L, Raught B, Lok BH

Neoplasia (New York, N.Y.)2025

DOI: 10.1016/j.neo.2025.101176 PMID: 40413955

OICR-41103 as a chemical probe for the DCAF1 WD40 domain.

Kimani SW, Noureldin M, Wilson B, Hoffer L, Green SR, Szewczyk MM, González-Álvarez H, Mohammed M, Chan M, Krausser C, Li ASM, Hajian T, Tucker S, Joshi D, Saraon P, Thériault B, Kim JS, Santhakumar V, Loppnau P, Li Y, Seitova A, Dong A, Kiyota T, Hammann T, Gehrtz P, Patel B, Rathod V, Vala A, Rout B, Jagodra P, Brown PJ, Aman A, Ramnauth J, Poda G, Uehling D, Arrowsmith CH, Barsyte-Lovejoy D, Marcellus R, Ackloo S, Mamai A, Al-Awar R, Halabelian L

Communications biology2025

DOI: 10.1038/s42003-025-08491-0 PMID: 40683980

Potent and selective SETDB1 covalent negative allosteric modulator reduces methyltransferase activity in cells.

Uguen M, Shell DJ, Silva M, Deng Y, Li F, Szewczyk MM, Yang K, Zhao Y, Stashko MA, Norris-Drouin JL, Waybright JM, Beldar S, Rectenwald JM, Mordant AL, Webb TS, Herring LE, Arrowsmith CH, Ackloo S, Gygi SP, McGinty RK, Barsyte-Lovejoy D, Liu P, Halabelian L, James LI, Pearce KH, Frye SV

Nature communications2025

DOI: 10.1038/s41467-025-57005-3 PMID: 39994194

A Target Class Ligandability Evaluation of WD40 Repeat-Containing Proteins.

Ackloo S, Li F, Szewczyk M, Seitova A, Loppnau P, Zeng H, Xu J, Ahmad S, Arnautova YA, Baghaie AJ, Beldar S, Bolotokova A, Centrella PA, Chau I, Clark MA, Cuozzo JW, Dehghani-Tafti S, Disch JS, Dong A, Dumas A, Feng JA, Ghiabi P, Gibson E, Gilmer J, Goldman B, Green SR, Guié MA, Guilinger JP, Harms N, Herasymenko O, Houliston S, Hutchinson A, Kearnes S, Keefe AD, Kimani SW, Kramer T, Kutera M, Kwak HA, Lento C, Li Y, Liu J, Loup J, Machado RAC, Mulhern CJ, Perveen S, Righetto GL, Riley P, Shrestha S, Sigel EA, Silva M, Sintchak MD, Slakman BL, Taylor RD, Thompson J, Torng W, Underkoffler C, von Rechenberg M, Walsh RT, Watson I, Wilson DJ, Wolf E, Yadav M, Yazdi AK, Zhang J, Zhang Y, Santhakumar V, Edwards AM, Barsyte-Lovejoy D, Schapira M, Brown PJ, Halabelian L, Arrowsmith CH

Journal of medicinal chemistry2025

DOI: 10.1021/acs.jmedchem.4c02010 PMID: 39495097

Characterization of PROTAC specificity and endogenous protein interactomes using ProtacID.

Shrestha S, Maitland MER, Jing L, Duan S, Nie DY, St-Germain J, Kanaris M, Barsyte-Lovejoy D, Arrowsmith CH, Raught B

Nature communications2025

DOI: 10.1038/s41467-025-63357-7 PMID: 40883309

PRMT5 promotes full-length HTT expression by repressing multiple proximal intronic polyadenylation sites

Yadav M, AlQazzaz MA, Ciamponi FE, Ho JC, Maron MI, Sababi AM, MacLeod G, Ahmadi M, Bullivant G, Tano V

Nucleic Acids Research (NAR)20254 citations

DOI: 10.1093/nar/gkaf347

Chemical technologies for controlling T cell glycosylation in health and disease

Co-investigatorCIHR2024Project Grant

Principal investigators: Edgar, Landon J

Keywords: Autoimmunity; Cancer; Dendritic Cells; Glycocalyx; Glycosylation; Glycosyltransferases; Immunostimulant; Nucleotide Sugars; Sialic Acid; T Cells

$956,250

Mapping pathogenic chromatin complexes in advanced prostate cancer with ChemBioID

SupervisorCIHR2023CIHR Fellowship

Principal investigators: Maitland, Matthew E

Keywords: Androgen Receptor; Bioid; Bivalent Compounds; Chemical Biology; Chromatin Complexes; Epigenetics; Prostate Cancer; Protein Interactions; Proteomics; Therapy Resistance

$135,000

Targeting protein arginine methylation in the 9p21.3 loss tumor microenvironment

Nominated PICIHR2023Project Grant

Principal investigators: Barsyte-Lovejoy, Dalia

Keywords: Pancreatic Cancer; Posttranslational Modifications; Tumor Immunity

$902,700

Targeting protein arginine methylation in the 9p21.3 loss tumor microenvironment

Nominated PICIHR2023PRIZE - Project Grant - PA: Prize: Early Career Investigator in Cancer

Principal investigators: Barsyte-Lovejoy, Dalia

Keywords: Pancreatic Cancer; Posttranslational Modifications; Tumor Immunity

$25,000

Targeting protein arginine methylation in tumor-associated macrophages

Nominated PICIHR2022Project Grant

Principal investigators: Barsyte-Lovejoy, Dalia

Keywords: Posttranslational Modifications; Splicing; Tumor Immunity

$100,000

Protein arginine methylation in nuclear organization, function, and stress response

Principal investigatorNSERC2021Discovery Grants Program - Individual

Principal investigators: Barsyte-Lovejoy, Dalia

$120,000

Harnessing tissue-specific expression of E3 ligases for selective protein degradation in cancer

SupervisorCIHR2021CIHR Fellowship

Principal investigators: Barghout, Samir

Keywords: Acute Lymphoblastic Leukemia; Cancer Therapy; Dcaf16; E3 Ligases; Epigenetics; Ezh2; Protacs; Small-Cell Lung Cancer; Targeted Protein Degradation; Ubiquitin System

$135,000

Protein arginine methylation in nuclear organization, function, and stress response

Principal investigatorNSERC2021Discovery Launch Supplement

Principal investigators: Barsyte-Lovejoy, Dalia

$12,500

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Something wrong or missing on this profile? Suggest a correction

Dalia Barsyte-Lovejoy

Research

Latest papers

Latest funding

Identification of E3 ligase substrates and PROTAC-induced ubiquitylation sites using proximity-based identification of ubiquitin sites (PrIUS).

ABHD2 activity is not required for the non-genomic action of progesterone on human sperm.

Development of a Dual Chemical Probe for the USP16 and HDAC6 Zinc-Finger Ubiquitin-Binding Domain.

Meeting report on FASEB protein arginine methylation: mechanism to therapeutics.

PRMT1 inhibitor MS023 suppresses RNA splicing to sensitize small cell lung cancer to DNA damaging agents.

OICR-41103 as a chemical probe for the DCAF1 WD40 domain.

Potent and selective SETDB1 covalent negative allosteric modulator reduces methyltransferase activity in cells.

A Target Class Ligandability Evaluation of WD40 Repeat-Containing Proteins.

Characterization of PROTAC specificity and endogenous protein interactomes using ProtacID.

PRMT5 promotes full-length HTT expression by repressing multiple proximal intronic polyadenylation sites

Chemical technologies for controlling T cell glycosylation in health and disease

Mapping pathogenic chromatin complexes in advanced prostate cancer with ChemBioID

Targeting protein arginine methylation in the 9p21.3 loss tumor microenvironment

Targeting protein arginine methylation in the 9p21.3 loss tumor microenvironment

Targeting protein arginine methylation in tumor-associated macrophages

Protein arginine methylation in nuclear organization, function, and stress response

Harnessing tissue-specific expression of E3 ligases for selective protein degradation in cancer

Protein arginine methylation in nuclear organization, function, and stress response

Frequent collaborators

Matthieu Schapira

Mathieu Lupien

Ahmed Aman

Cheryl Arrowsmith

Brian Raught

Nada Jabado

Igor Jurisica

Brian Wilson

Anne-Claude Gingras

Mark Bernstein

Jean Michaud

David Uehling

Rachel Harding

Benjamin Haibe-Kains

Caroline Schild-Poulter

Stéphane Richard

Annie Huang

Razqallah Hakem

Eric Bouffet

Stéphane Richard

Robert Hammond

Donna Johnston

Marius Locke

Livia Garzia

Joanne Kotsopoulos

Amy Caudy

Colby Zaph

Denise Belsham

Jennifer Chan

Arturas Petronis